Where our dosing codex data comes from, and how to verify it yourself.
Our dosing codex is a reference aggregation, not original clinical research. Each entry is compiled from a mix of sources depending on the compound: peer-reviewed literature and clinical-trial data for the well-studied compounds, and aggregated community-reported protocols for the research-only ones that have little or no formal human dosing literature.
Because the figures are aggregated rather than taken from a single paper per line, we use confidence tags instead of per-line citations. The tag tells you how much formal backing a compound's dosing actually has, so you know how much weight to give it before verifying yourself.
Backed by human clinical trials and/or approved-drug prescribing information. Dose ranges reflect published trial protocols. Examples: the GLP-1 family, tesamorelin, HGH, HCG, oxytocin.
Some research exists — often preclinical (animal/in-vitro) or small early human studies — but robust human dosing data is limited. Dose ranges blend what literature exists with established community use. Examples: BPC-157, TB-500, MOTS-c, the GH secretagogues.
Little or no formal human dosing literature. Figures come from aggregated community protocols and should be treated as anecdotal, not clinically validated. Examples: most Khavinson bioregulators and multi-compound blends.
We actively encourage you to check our figures against primary sources. These are the databases researchers use — all free and searchable:
💡 Tip: search the compound's full chemical name (not the brand or street name) for the best results. For trial-stage compounds, ClinicalTrials.gov often has the exact escalation schedules we reference.